Can-Fite BioPharma Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.4M
- Price
- $2.10
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.87%
- Volume
- 44.4K
About
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
Quick stats
Shares outstanding3.0M
Computed float1.3M
Float / shares43.1%
Cash runway (months)8.7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001536196
Websitehttps://www.canfite.com
AI Summary
AI-generated1/23
minorbullishclinical trial
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
A peer-reviewed case report published in the Japanese Journal of Gastroenterology and Hepatology describes a patient with advanced decompensated liver cirrhosis whose ascites resolved and esophageal varices regressed during treatment with Can-Fite's Namodenoson, allowing discontinuation of diuretic therapy.
After approximately 28 months of Namodenoson treatment the patient remained clinically stable and underwent successful orthotopic liver transplantation in January 2026, with favorable post-transplant recovery.
Treating physician Prof. Ohad Etzion noted the improvements in portal hypertension complications occurred despite continued deterioration in underlying liver function, and while a single-patient observation, the findings support further evaluation of Namodenoson in advanced liver disease.
Namodenoson is separately in a pivotal Phase 3 trial for hepatocellular carcinoma and a Phase 2b trial for MASH, while Can-Fite's lead candidate Piclidenoson is in a pivotal Phase III psoriasis study.
Red flags
- Evidence is a single-patient case report, not controlled trial data — limited statistical significance
- Clinical-stage company with stated history of losses and need for additional capital; risk of not satisfying NYSE American continued listing requirements noted in forward-looking statements